Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
NCT ID: NCT04399577
Last Updated: 2020-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
39 participants
INTERVENTIONAL
2017-07-01
2019-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
NCT05100043
Triple Antigen vs Monoantigen Immunotherapy for Warts
NCT05254561
Sclerotherapy and Candida Antigen in Treatment of Common Warts
NCT06749665
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
NCT05291845
Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts
NCT05429151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wart Patients
Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
Candida antigen
Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candida antigen
Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Fever
* Immunosuppressive disorders
* Previous wart therapy in the last month
9 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha M Hammad, MD
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig University Faculty of Medicine
Zagazig, Sharqia Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hammad NM, Abdelhadi AA, Fawzy MM, Marei A. Complement component 3c and tumor necrosis factor-alpha systemic assessment after Candida antigen immunotherapy in cutaneous warts. Braz J Microbiol. 2020 Dec;51(4):1673-1681. doi: 10.1007/s42770-020-00322-0. Epub 2020 Jun 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3140/23-10-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.